Avac Event

Conference on Retroviruses and Opportunistic Infections (CROI 2026)

CROI Conference

Conference Background

The Conference on Retroviruses and Opportunistic Infections (CROI) was established in 1993 to provide a forum for basic scientists and clinical investigators to present, discuss, and critique their investigations into the epidemiology and biology of human retroviruses and associated diseases. The synergy of basic science and clinical investigation has been a major contributor to the success of the meeting. CROI has facilitated the presentation of important discoveries in the field, thereby accelerating progress in HIV and AIDS research. CROI highlights the latest research in HIV, hepatitis viruses, SARS-CoV-2 (including long COVID), mpox, and their related conditions. Learn more on the CROI website.

AVAC Infographics

Going to CROI? AVAC’s up-to-date infographics — on the research & development pipeline, prevention options, and the impact of US funding cuts — are available here for use in conference presentations. We constantly update these graphics, so check back for updates. The latest version of the deck will be available here.

Download Slide Deck

Community Breakfast Meetings

The Community Breakfast Clubs are virtual webinars coordinated by the CROI Community Liaisons, the European AIDS Treatment Group, AVAC, and their global collaborators. They feature researchers and advocates discussing some of the most consequential science being presented at CROI.

  • Spotlight on HIV Cure Science at CROI 2026: What’s new and & what’s next?
    Monday, February 23, 2026, 7:00-8:00AM Mountain Time
    Registration
  • Prevention Science at CROI 2026: From innovation to impact
    Tuesday, February 24, 2026
    Registration
  • Advances in Long-Acting HIV Treatment: Science, delivery and equity
    Wednesday, February 25, 2026
    Registration

People’s Research Agenda

2025 Update

The People’s Research Agenda sets out a people-centered framework for equitable and accelerated R&D and product introduction. It tracks the science, shows where investments align—or fail to align—with community-defined priorities, and spotlights critical gaps in the pipeline of prevention options needed to meet the diverse realities of all populations.

Read the 2025 Update

The original 2024 report is also available.

At A Glance: The MPT R&D Pipeline

This graphic shows the status of products in development.

HIV Prevention Pipeline: Products to Watch

From the People’s Research Agenda, this graphic tracks the pipeline of potential new HIV prevention options across broadly neutralizing antibodies, preventive vaccines, pre-exposure prophylaxis, and multipurpose technologies.

An interactive version of this graphic is available.

People’s Research Agenda Pipeline Tracker

This tracker provides details on key HIV prevention trials to watch. It is updated on a quarterly and ad-hoc basis as developments occur.

If you would like to share additional information or corrections, please email Breanne at [email protected]. For more, visit the People’s Research Agenda.

View Tracker

Spotlight on MPTs Addressing STIs

This graphic outlines the development journey of multipurpose technologies (MPTs) that guard against STIs, including HIV, while also preventing pregnancy. It tracks the advancement of various potential products through different trial stages, emphasizing their combined protective roles.

PrEP Price Comparison

Comparing the annual price of oral TDF/FTC vs. the dapivirine vaginal ring and injectable cabotegravir. For product approvals, volumes, implementation, and price comparisons of long-acting PrEP, visit our dashboard on PrEPWatch.org.

Broadly Neutralizing Antibody Combinations

Overview of the combinations of broadly neutralizing antibodies (bNAbs) under investigation in early clinical studies for HIV prevention.

Years Ahead in HIV Prevention Research: Time to Market

This timeline shows the potential time points when the next-generation of HIV prevention options might find their way into new programs.

ARV-Based and Multipurpose Prevention Technology R&D Pipeline

The pipeline of non-vaccine HIV prevention products includes oral pills, vaginal rings, vaginal and rectal gels, vaginal films, long-acting injectable antiretrovirals and more. Also pictured are the range of MPTs in development that aim to reduce the risk of HIV and STIs and/or provide effective contraception for women.

Click here for a view of all large-scale prevention trials.